Peppermint oil (Mintoil®) in the treatment of irritable bowel syndrome. A prospective double blind placebo controlled randomized trial

Cappello, G.; Coraggio, D.; Berardinis, G. De; Spezzaferro, M.; Grossi, L.; Marzio, L.

doi:10.1016/s1590-8658(06)80548-7

Cited by 11 publications

(15 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides its importance in cool sensation, menthol is the major active ingredient of various herbal medicines. Since antiquity, peppermint (a major constituent of which is menthol) has been used widely for various medicinal purposes ranging from management of musculoskeletal pain and the common cold to the treatment of gastrointestinal disorders such as nausea, vomiting, and irritable bowel syndrome (for reviews, see Grigoleit and Grigoleit, 2005;Cappello et al, 2007;Patel et al, 2007;and Haniadka et al, 2012). However, the cellular and molecular targets mediating the beneficial effects of peppermint and other menthol-containing products on gastrointestinal disorders are currently unknown (De Araújo et al, 2011).…”

Section: Introductionmentioning

confidence: 99%

Menthol Inhibits 5-HT₃Receptor–Mediated Currents

Ashoor

Nordman

Veltri

et al. 2013

J Pharmacol Exp Ther

View full text Add to dashboard Cite

The effects of alcohol monoterpene menthol, a major active ingredient of the peppermint plant, were tested on the function of human 5-hydroxytryptamine type 3 (5-HT 3 ) receptors expressed in Xenopus laevis oocytes. 5-HT (1 mM)-evoked currents recorded by two-electrode voltage-clamp technique were reversibly inhibited by menthol in a concentration-dependent (IC 50 5 163 mM) manner. The effects of menthol developed gradually, reaching a steadystate level within 10-15 minutes and did not involve G-proteins, since GTPgS activity remained unaltered and the effect of menthol was not sensitive to pertussis toxin pretreatment. The actions of menthol were not stereoselective as (2), (1), and racemic menthol inhibited 5-HT 3 receptor-mediated currents to the same extent.Menthol inhibition was not altered by intracellular 1,2-bis(oaminophenoxy)ethane-N,N,N9,N9-tetraacetic acid injections and transmembrane potential changes. The maximum inhibition observed for menthol was not reversed by increasing concentrations of 5-HT. Furthermore, specific binding of the 5-HT 3 antagonist [ 3 H]GR65630 was not altered in the presence of menthol (up to 1 mM), indicating that menthol acts as a noncompetitive antagonist of the 5-HT 3 receptor. Finally, 5-HT 3 receptor-mediated currents in acutely dissociated nodose ganglion neurons were also inhibited by menthol (100 mM). These data demonstrate that menthol, at pharmacologically relevant concentrations, is an allosteric inhibitor of 5-HT 3 receptors.

show abstract

Section: Introductionmentioning

confidence: 99%

Menthol Inhibits 5-HT₃Receptor–Mediated Currents

Ashoor

Nordman

Veltri

et al. 2013

J Pharmacol Exp Ther

View full text Add to dashboard Cite

show abstract

“…Findings of several recent systematic and nonsystematic reviews support the safe and effective use of enteric‐coated PO for attenuating GI spasms and pain in adult populations (≥18 years) with IBS for doses up to 1200 mg/d . In 2014, PO received a positive evaluation from the American College of Gastroenterology Task Force, citing 5 randomized controlled trials (involving 482 patients) supporting the finding that “PO is superior to placebo in improving IBS symptoms.” Collectively, studies support the use of enteric‐coated PO to improve total IBS symptoms score and symptoms of IBS (most commonly pain) with minimal adverse effects. Studies have mixed findings regarding QOL, with results supporting significant improvement and no change…”

Section: Methodsmentioning

confidence: 82%

“…Liu et al found that 4 weeks of PO supplementation (187 mg, 3 or 4 doses per day) resulted in greater improvements in patient‐reported IBS symptoms than the placebo group, including abdominal pain, distension, and stool frequency. Capello and colleagues similarly observed that consumption of PO (225 mg, twice daily) for 4 weeks significantly reduced the total IBS symptoms score at 4 weeks vs placebo. Benefits of PO supplementation lasted 1 month after therapy in >50% of patients.…”

Section: Methodsmentioning

confidence: 90%

Natural Bioactive Food Components for Improving Enteral Tube Feeding Tolerance in Adult Patient Populations

2017

View full text Add to dashboard Cite

Tube feeding (TF) is the most common form of nutrition support. In recent years, TF administration has increased among patient populations within and outside hospital settings, in part due to greater insurance coverage, reduced use of parenteral nutrition, and improved formularies suitable for sole source nutrition. With increasing life expectancy and improved access to TFs, the number of adults dependent on enteral nutrition is expected to grow. However, enteral TF intolerance (ETFI) is the most common complication of TFs, typically presenting with at least 1 adverse gastrointestinal event, including nausea, diarrhea, and constipation. ETFI often leads to reductions in TF volume with associated energy and protein deficits. Potentially ensuing malnutrition is a major public health concern due its effects on increased risk of morbidity and mortality, infections, prolonged hospital length of stay, and higher healthcare costs. As such, there is a need for intervention strategies to prevent and reduce ETFI. Incorporating whole foods with bioactive properties is a promising strategy. Emerging research has elucidated bioactive properties of whole foods with specific benefits for the prevention and management of adverse gastrointestinal events commonly associated with TFs. However, lack of evidence-based recommendations and technological challenges have limited the use of such foods in commercial TF formulas. This review addresses research gaps by discussing 5 whole foods (rhubarb, banana, curcumin, peppermint oil, and ginger) with bioactive attributes identified through literature searches and clinical experience as having substantial scientific rationale to consider their application for ETFI in adult populations. (Nutr Clin Pract. 2018;33:107-120) Keywords enteral nutrition; enteral formulas; tube feeding; dietary supplements; digestive signs and symptoms SummaryTube feeding (TF) is the most common form of nutrition support. In recent years, TF administration has increased among patient populations within and outside hospital settings, in part due to greater insurance coverage, reduced use of parenteral nutrition (PN), and improved formularies suitable for sole source nutrition. With increasing life expectancy and improved access to TFs, the number of adults dependent on enteral nutrition (EN) is expected to grow. However, enteral TF intolerance (ETFI) is the most common complication of TFs, typically presenting with at least 1 adverse gastrointestinal (GI) event, including nausea, diarrhea, and constipation. ETFI often leads to reductions in TF volume with associated energy and protein deficits. Potentially ensuing malnutrition is a major public health concern due its effects on increased risk of morbidity and mortality, infections, prolonged hospital length of stay, and higher healthcare costs. As such, there is a need for intervention strategies to prevent and reduce ETFI. Incorporating whole foods with bioactive properties is a promising strategy. Emerging research has elucidated bioactive properties ...

show abstract

“…The most recent review included 5 trials for a total of 482 patients (107)(108)(109)(110)(111); it showed a statistically significant positive effect of peppermint oil versus placebo, with a NNT of 3 (95% CI: 2-4) (90). However, there was significant heterogeneity among studies.…”

Section: Efficacymentioning

confidence: 99%

Clinical Practice Guideline: Irritable bowel syndrome with constipation and functional constipation in the adult

Mearin¹,

Ciriza²,

Mínguez³

et al. 2016

Rev Esp Enferm Dig

103

151

View full text Add to dashboard Cite

In this Clinical Practice Guideline we discuss the diagnostic and therapeutic approach of adult patients with constipation and abdominal complaints at the confluence of the irritable bowel syndrome spectrum and functional constipation. Both conditions are included among the functional bowel disorders, and have a significant personal, healthcare, and social impact, affecting the quality of life of the patients who suffer from them. The first one is the irritable bowel syndrome subtype, where constipation represents the predominant complaint, in association with recurrent abdominal pain, bloating, and abdominal distension. Constipation is characterized by difficulties with or low frequency of bowel movements, often accompanied by straining during defecation or a feeling of incomplete evacuation. Most cases have no underlying medical cause, and are therefore considered as a functional bowel disorder. There are many clinical and pathophysiological similarities between both disorders, and both respond similarly to commonly used drugs, their primary difference being the presence or absence of pain, albeit not in an "all or nothing" manner. Severity depends not only upon bowel symptom intensity but also upon other biopsychosocial factors (association of gastrointestinal and extraintestinal symptoms, grade of involvement, and perception and behavior variants). Functional bowel disorders are diagnosed using the Rome criteria. This Clinical Practice Guideline has been made consistent with the Rome IV criteria, which were published late in May 2016, and discuss alarm criteria, diagnostic tests, and referral criteria between Primary Care and gastroenterology settings. Furthermore, all the available treatment options (exercise, fluid ingestion, diet with soluble fiber-rich foods, fiber supplementation, other dietary components, osmotic or stimulating laxatives, probiotics, antibiotics, spasmolytics, peppermint essence, prucalopride, linaclotide, lubiprostone, biofeedback, antidepressants, psychological therapy, acupuncture, enemas, sacral root neurostimulation, surgery) are discussed, and practical recommendations are made regarding each of them.

show abstract

Peppermint oil (Mintoil®) in the treatment of irritable bowel syndrome. A prospective double blind placebo controlled randomized trial

Cited by 11 publications

References 0 publications

Menthol Inhibits 5-HT₃Receptor–Mediated Currents

Menthol Inhibits 5-HT₃Receptor–Mediated Currents

Natural Bioactive Food Components for Improving Enteral Tube Feeding Tolerance in Adult Patient Populations

Clinical Practice Guideline: Irritable bowel syndrome with constipation and functional constipation in the adult

Contact Info

Product

Resources

About

Peppermint oil (Mintoil®) in the treatment of irritable bowel syndrome. A prospective double blind placebo controlled randomized trial

Cited by 11 publications

References 0 publications

Menthol Inhibits 5-HT3Receptor–Mediated Currents

Menthol Inhibits 5-HT3Receptor–Mediated Currents

Natural Bioactive Food Components for Improving Enteral Tube Feeding Tolerance in Adult Patient Populations

Clinical Practice Guideline: Irritable bowel syndrome with constipation and functional constipation in the adult

Contact Info

Product

Resources

About

Menthol Inhibits 5-HT₃Receptor–Mediated Currents

Menthol Inhibits 5-HT₃Receptor–Mediated Currents